The stock price of Ensysce Biosciences Inc (NASDAQ: ENSC) has dropped by -12.88 compared to previous close of 2.29. Despite this, the company has seen a fall of -22.07% in its stock price over the last five trading days. accessnewswire.com reported 2025-03-31 that SAN DIEGO, CA / ACCESS Newswire / March 31, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (“Ensysce” or the “Company”), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that it has entered into definitive agreements, providing the Company with an aggregate gross proceeds of approximately $1.1 million, for the issuance and sale of an aggregate of 315,188 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $3.49 per share (or common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company has also agreed to issue and sell unregistered Series A-5 warrants to purchase up to an aggregate of 315,188 shares of common stock and unregistered Series A-6 warrants to purchase up to an aggregate of 315,188 shares of common stock.
Is It Worth Investing in Ensysce Biosciences Inc (NASDAQ: ENSC) Right Now?
The 36-month beta value for ENSC is also noteworthy at 1.07. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ENSC is 1.69M, and at present, short sellers hold a 1.30% of that float. The average trading volume of ENSC on April 08, 2025 was 37.37K shares.
ENSC’s Market Performance
ENSC stock saw a decrease of -22.07% in the past week, with a monthly decline of -60.26% and a quarterly a decrease of -78.20%. The volatility ratio for the week is 13.98%, and the volatility levels for the last 30 days are 10.97% for Ensysce Biosciences Inc (ENSC). The simple moving average for the past 20 days is -39.91% for ENSC’s stock, with a -67.91% simple moving average for the past 200 days.
ENSC Trading at -58.76% from the 50-Day Moving Average
After a stumble in the market that brought ENSC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.40% of loss for the given period.
Volatility was left at 10.97%, however, over the last 30 days, the volatility rate increased by 13.98%, as shares sank -58.59% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -73.61% lower at present.
During the last 5 trading sessions, ENSC fell by -21.87%, which changed the moving average for the period of 200-days by -75.85% in comparison to the 20-day moving average, which settled at $3.32. In addition, Ensysce Biosciences Inc saw -75.49% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ENSC
Current profitability levels for the company are sitting at:
- -13.8 for the present operating margin
- -0.94 for the gross margin
The net margin for Ensysce Biosciences Inc stands at -16.38. The total capital return value is set at -1.99. Equity return is now at value -471.82, with -192.33 for asset returns.
Based on Ensysce Biosciences Inc (ENSC), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -24.87. The debt to equity ratio resting at 0.08. The interest coverage ratio of the stock is -5.22.
Currently, EBITDA for the company is -6.73 trillion with net debt to EBITDA at 0.66. When we switch over and look at the enterprise to sales, we see a ratio of 0.48. The receivables turnover for the company is 3.93for trailing twelve months and the total asset turnover is 0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.42.
Conclusion
In summary, Ensysce Biosciences Inc (ENSC) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
